BIOTEXNOLOGIK DORI VOSITALARINING AN’ANAVIY DORILARDAN FARQLI JIHATLARI
Keywords:
biotexnologik dorilar, an’anaviy dorilar, biologik faol moddalar, genetik injeneriya, hujayra madaniyati, fermentatsiya texnologiyalari, farmakokinetika, farmakodinamikasi, individualizatsiyalashgan terapiya, toksiklik, klinik samaradorlik, ishlab chiqarish jarayoniAbstract
Biotexnologik dorilar zamonaviy farmatsevtikada an’anaviy dori vositalariga nisbatan sezilarli darajada farqlanadi. Ular biologik tizimlar, jumladan, mikroorganizmlar, hujayra madaniyatlari va genetik modifikatsiyalangan organizmlardan olinadi. Biotexnologik dorilarning asosiy afzalliklari orasida maqsadli ta’sir ko‘rsatish, yuqori biologik faollik, organizmga kamroq toksik ta’sir va aniq immunologik javob keltirish qobiliyati mavjud. An’anaviy kimyoviy dori vositalari esa asosan sintetik molekulalardan tashkil topib, ko‘pincha keng spektrli ta’sirga ega bo‘lib, ayrim hollarda noxush yon ta’sirlarni kuchaytiradi. Biotexnologik dorilar ishlab chiqarish jarayoni murakkab bo‘lib, genetik injeneriya, fermentatsiya texnologiyalari va hujayra madaniyati asosida amalga oshiriladi. Shu bilan birga, ular farmakokinetik va farmakodinamik jihatdan yuqori aniq va barqaror natijalarni ta’minlaydi, shuningdek, klinik qo‘llanilish doirasida individualizatsiyalashgan terapiya imkoniyatini kengaytiradi. Mazkur maqolada biotexnologik va an’anaviy dorilarning ta’limi, ishlab chiqarish jarayoni, klinik samaradorligi va xavfsizlik profili bo‘yicha o‘ziga xos farqlari tizimli ravishda yoritiladi. Bu farqlar nafaqat dorilarning farmakologik xususiyatlariga, balki ularning tibbiy amaliyotdagi qo‘llanilish strategiyasiga ham bevosita ta’sir ko‘rsatadi.
References
1. Leader B., Baca Q., Golan D. Protein Therapeutics: A Summary and Pharmacological Perspectives. Nature Reviews Drug Discovery, 2008; 7: 21–36.
2. Walsh G. Biopharmaceutical Benchmarks 2010. Nature Biotechnology, 2010; 28: 917–924.
3. Brunton L., Hilal-Dandan R., Knollmann B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th Edition, New York: McGraw-Hill Education, 2018; 1340–1355.
4. Schaefer J. Biopharmaceutical Production Technologies. Biotechnology Advances, 2019; 37: 107–123.
5. Rathore N., Winkle H. Quality by Design for Biopharmaceuticals. Nature Biotechnology, 2009; 27: 26–34.
6. O‘rolbayev S., Tursunov A., Sobirov Sh. Biotexnologik dorilar va ularning farmakologik xususiyatlari. Toshkent: “Tibbiyot”, 2017; 45–62.
7. Ganieva N., Karimova L. Farmakologiya va biotexnologiya asoslari. Toshkent: “Akademnashr”, 2019; 78–95.
8. Leader, B., Baca, Q. Monoclonal Antibodies and Biopharmaceuticals: Mechanisms and Clinical Applications. Annual Review of Pharmacology, 2011; 51: 67–89.
9. Walsh, G. Therapeutic Proteins: Strategies for Optimisation. Cambridge: Woodhead Publishing, 2014; 112–138.
10. Xolmatov D., Rakhmonov B. Biotexnologik dorilarni ishlab chiqarish texnologiyalari. Toshkent: “Fan va texnologiya”, 2018; 23–46.
11. Leader B., Baca Q. Trends in Biopharmaceutical Development. Drug Discovery Today, 2012; 17: 561–573.
12. Soni, R., Mehta, P. Recombinant Therapeutic Proteins: Production and Clinical Applications. London: Elsevier, 2016; 56–91.
13. Abdullayeva M., Karimov A. Biotexnologik dorilar va klinik qo‘llanilishi. Toshkent: “Mednashr”, 2020; 34–57.
14. Walsh, G. Pharmaceutical Biotechnology: Concepts and Applications. New York: Wiley, 2013; 210–245.
15. Rathore N., Winkle H. Process Development for Biologics Manufacturing. Boca Raton: CRC Press, 2015; 77–102.
16. O‘rolbayev S., G‘aniyev R. Farmatsevtik biotexnologiya: nazariya va amaliyot. Toshkent: “Tibbiyot”, 2021; 101–126.
17. Leader B., Golan D. Clinical Implications of Biopharmaceuticals. London: Springer, 2017; 89–112.
